Title : Blood cancer as hematopoietic state-space distortion: A B-Bio framework for leukemia and lymphoma modeling using multimodal patient-derived evidence, demonstrated in BVidAL Clinical Software Suite
Abstract:
Blood cancers such as leukemia and lymphoma do not usually present as a single localized solid tumor, but as systemic disorders of hematopoietic, immune, marrow, lymphoid, and molecular organization. This presentation proposes a B-Bio framework for modeling blood cancer as hematopoietic state-space distortion, where abnormal blood-cell evolution, marrow disruption, immune-system coupling, genomic alteration, lymphoid involvement, and treatment-response behavior are interpreted as connected disease-state transitions. The proposed work uses real de-identified patient-derived data from publicly available hematology, oncology, pathology, and imaging sources to support and demonstrate the framework, thus the evidentiary basis may include bone-marrow cytomorphology, blood or marrow cell morphology, genomic evidence, lymphoma-related PET/CT imaging, clinical laboratory-style features, and, whole-slide or slide-microscopy histopathology. These data streams will be used to represent leukemia and lymphoma as progressive disturbances in blood-cell lineage organization, marrow or lymphoid architecture, immune regulation, cellular proliferation, and systemic disease behavior. Within the B-Bio interpretation, leukemia may be modeled as abnormal hematopoietic cell-state expansion and marrow-level functional distortion, while lymphoma may be modeled as lymphoid-system state disruption with possible nodal, tissue, or systemic imaging correlates. Genomic and molecular evidence may be used to support disease-state stratification, while cytomorphology and pathology evidence may support cell-level and tissue-level interpretation. PET/CT or other imaging evidence may support systemic distribution and response-monitoring concepts where appropriate. BVidAL Clinical Software Suite, a fully free SaMD (Software as a Medical Device) will be used in a research-oriented environment to organize these multimodal evidence streams into an interpretable blood-cancer modeling workflow. The objective is not to replace established hematology, oncology, pathology, or radiology practice, but to demonstrate how patient-derived data can be connected within a unified B-Bio disease-state model for exploratory validation, computational biomedical research, and academic study.
